Effects of Cannabidiol and a Novel Cannabidiol Analog against Tactile Allodynia in a Murine Model of Cisplatin-Induced Neuropathy: Enhanced Effects of Sub-Analgesic Doses of Morphine Hannah Marie Harris, Waseem Gul, Mahmoud A. ElSohly, Kenneth J. Sufka Medical Cannabis and Cannabinoids, 2018, 1, 54–59 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489077 Abstract Objective : This research examined whether a cannabidiol (CBD)-opioid pharmacotherapy could attenuate cisplatin-induced tactile allodynia. Methods : Mice (C57BL/6) were given 6 doses of 2.3 mg/kg cisplatin intraperitoneally (IP) on alternating days to induce tactile allodynia as quantified using an electric von Frey (eVF). Test groups in Experiment 1 received either vehicle, 0.1 [...]
Lire la suitePharmacokinetics and Tolerability of Δ9-THC-Hemisuccinate in a Suppository Formulation as an Alternative to Capsules for the Systemic Delivery of Δ9-THC Mahmoud A. ElSohly, Waseem Gul, Larry A. Walker Medical Cannabis and Cannabinoids, 2018, 1, 44–53 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489037 Abstract The objectives of this study were: (1) to assess the safety, tolerability, and pharmacokinetics of ascending doses of Δ9- tetrahydrocannabinol-hemisuccinate (THC-HS) after rectal administration as suppositories in male volunteers; and (2) to compare the pharmacokinetics of oral administration of Δ9-tetrahydrocannabinol (Δ9-THC) with an equivalent amount of Δ9-THC delivered as THC-HS via the suppository formulation. In support of the pharmacokinetic evaluations, [...]
Lire la suiteHuman Pharmacokinetics and Adverse Effects of Pulmonary and Intravenous THC-CBD Formulations Pascale Meyer, Manuela Langos, Rudolf Brenneisen Medical Cannabis and Cannabinoids, 2018, 1, 36–43 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489034 Abstract Background : Due to variable absorption and extensive firstpass metabolism, the bioavailability of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is low, and, therefore, alternative application forms are necessary. Methods : In an open-label, 2-period phase-1 study on 11 healthy volunteers, a combination of THC and CBD was compared by pulmonary (inh) and intravenous (iv) application. The liquid aerosol was produced by an in vitro validated pressurized metered-dose inhaler (pMDI) device, releasing 41–44% [...]
Lire la suiteMedical Cannabis and Cannabinoids : An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon? Magdalena Grill, Carina Hasenoehrl, Martin Storr, Rudolf Schicho Medical Cannabis and Cannabinoids, 2018, 1, 28–35 © 2018 The Author(s) Published by S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/mca DOI: 10.1159/000489036 Abstract : In the past few years, we have witnessed a surge of new reports dealing with the role of cannabinoids, synthetic as well as herbal, in the mechanisms of inflammation and carcinogenesis. However, despite the wealth of in vitro data and anecdotal reports, evidence that cannabinoids could act as beneficial drugs in inflammatory bowel disease (IBD) or in [...]
Lire la suiteExtractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses Melissa M. Lewis-Bakker, Yi Yang, Rupali Vyawahare, and Lakshmi P. Kotra Cannabis and Cannabinoid Research, 2019, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0067 Abstract Introduction : Phytocannabinoids, characteristic compounds produced by medical cannabis, interact with cannabinoid (CB) receptors (CB1 and CB2) as well as other receptor systems to exhibit their corresponding pharmacological effects. In their natural form, CBs such as D9-tetrahydrocannabinolic acid and cannabidiolic acid are inactive at these receptors, while their decarboxylated forms (D9 tetrahydrocannabinol and cannabidiol, respectively) are potent ligands at CB receptors. Thus, extraction and [...]
Lire la suiteCBD Gel Promising for Fragile X Syndrome Megan Brooks Medscape, 2019 https://www.medscape.com/viewarticle/913267?nlid=129947_2052&src=WNL_mdplsnews_190524_mscpedit_psyc&uac=292598PZ&spon=12&impID=1974025&faf=1 SAN FRANSICO — A clear transdermal cannabidiol (CBD) gel (ZYN002, Zynerba Pharmaceuticals) improved emotional and behavioral symptoms experienced by children and adolescents with fragile X syndrome in a phase 2 open-label study, the company reports. ZYN002 met its primary endpoint, with patients demonstrating a 46% improvement in the total score on the Anxiety, Depression, and Mood Scale (ADAMS) at week 12 compared to baseline. ZYN002 also led to meaningful improvements in all measures of the Aberrant Behavior Checklist for Fragile X (ABC-FXS), which addresses the key symptoms of fragile X syndrome, including social avoidance, [...]
Lire la suiteMedical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland Aleksi Mikael Markunpoika Hupli Medical Cannabis and Cannabinoids, 2018, 1, 112–118 DOI: 10.1159/000495307 https://www.karger.com/Article/FullText/495307 Abstract : This paper presents a detailed patient case report of a male patient who was diagnosed in adulthood (aged 33) with attention deficit hyperactivity disorder (ADHD) and treated initially with immediate-release methylphenidate (Ritalin® 10 mg twice daily). After experiencing adverse effects from prolonged use of this medication and afterwards other medications that were prescribed as alternatives, the patient discovered that cannabinoid therapeutics (CT) had been experimented inside the EU area to treat patients with [...]
Lire la suiteCannabinoid Hyperemesis Joseph V. Pergolizzi Jr., Jo Ann LeQuang, John F. Bisney Medical Cannabis and Cannabinoids, 2018, 1, 73–95 DOI: 10.1159/000494992 https://www.karger.com/Article/FullText/494992 Abstract : Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in which a long-term cannabis user suffers an episode of intractable vomiting that may last days separated by longer asymptomatic periods of weeks or months. Cannabinoids are often utilized for their antiemetic properties, so CHS can be a puzzling condition, and the diagnosis of CHS may be disputed by patients. Unlike other cyclic vomiting syndromes, CHS can be relieved by hot showers or topical capsaicin. Abstinence from cannabinoids causes CHS to resolve, sometimes in [...]
Lire la suiteMedical Cannabis Safe, Effective for Neurologic Symptoms in the Elderly Caroline Cassels Medscape Medical News, 2019 https://www.medscape.com/viewarticle/912624_print PHILADELPHIA — Medical cannabis may be safe and effective in the treatment of a wide range of chronic symptoms related to various neurologic illnesses in elderly patients, early research suggests. In a preliminary study, investigators at the Dent Neurologic Institute in Buffalo, New York, found that the drug provided elderly patients relief from chronic pain, sleep disorders, and anxiety related to diseases such as amyotrophic lateral sclerosis, Parkinson disease, neuropathy, spinal cord damage, and multiple sclerosis. "Our findings show that medical marijuana is well-tolerated in people age 75 and [...]
Lire la suiteThe Trouble with CBD Oil Arno Hazekamp Medical Cannabis and Cannabinoids, 2018, 1, 65–72 DOI: 10.1159/000489287 Abstract In just a few years, cannabidiol (CBD) has become immensely popular around the world. After initially being discovered as an effective self-medication for Dravet syndrome in children, CBD is now sold and used to treat a wide range of medical conditions and lifestyle diseases. The cannabinoid CBD, a non psychoactive isomer of the more infamous tetrahydrocannabinol (THC), is available in a growing number of administration modes, but the most commonly known is CBD oil. There are currently dozens, if not hundreds, of producers and sellers of CBD oils [...]
Lire la suite